Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer

Published:2021-07-01 Issue:7 Volume:7 Page:1005
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Feng Felix Y.¹,Thomas Shibu²,Saad Fred³,Gormley Michael²,Yu Margaret K.⁴,Ricci Deborah S.²,Rooney Brendan⁵,Brookman-May Sabine⁴,McCarthy Sharon⁶,Olmos David⁷⁸,Chowdhury Simon⁹,Hadaschik Boris¹⁰¹¹,Liu Yang¹²,Davicioni Elai¹²,Smith Matthew R.¹³¹⁴,Small Eric J.¹

Affiliation:

1. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

2. Janssen Research & Development, Spring House, Pennsylvania

3. Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada

4. Janssen Research & Development, Los Angeles, California

5. Janssen Research & Development, High Wycombe, United Kingdom

6. Janssen Research & Development, Raritan, New Jersey

7. Spanish National Cancer Research Centre, Madrid, Spain

8. Institituto de Investigación Biomédica de Málaga, Málaga, Spain

9. Guy’s, King’s and St. Thomas’ Hospitals, Great Maze Pond, London, United Kingdom

10. West German Cancer Center, Department of Urology, University of Duisburg-Essen, Essen, Germany

11. Department of Urology, University Hospital Heidelberg, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany